Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
<p>Abstract</p> <p>There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse&q...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2005-09-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/4/1/14 |
| _version_ | 1818664304110469120 |
|---|---|
| author | Tenenbaum Alexander Motro Michael Fisman Enrique Z |
| author_facet | Tenenbaum Alexander Motro Michael Fisman Enrique Z |
| author_sort | Tenenbaum Alexander |
| collection | DOAJ |
| description | <p>Abstract</p> <p>There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biological role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs – the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clinical trials and may be effective in reducing cardiovascular risk, but their long-term clinical effects are still unknown. A number of glitazars have presented problems at a late stage of clinical trials because of serious side-effects (including ragaglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan – (alpha, beta/delta, gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clinically tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clinical evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders.</p> |
| first_indexed | 2024-12-17T05:30:36Z |
| format | Article |
| id | doaj.art-b41b8b94ad1649ecb6c6f43e23c95577 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-17T05:30:36Z |
| publishDate | 2005-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-b41b8b94ad1649ecb6c6f43e23c955772022-12-21T22:01:44ZengBMCCardiovascular Diabetology1475-28402005-09-01411410.1186/1475-2840-4-14Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessonsTenenbaum AlexanderMotro MichaelFisman Enrique Z<p>Abstract</p> <p>There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biological role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs – the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clinical trials and may be effective in reducing cardiovascular risk, but their long-term clinical effects are still unknown. A number of glitazars have presented problems at a late stage of clinical trials because of serious side-effects (including ragaglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan – (alpha, beta/delta, gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clinically tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clinical evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders.</p>http://www.cardiab.com/content/4/1/14 |
| spellingShingle | Tenenbaum Alexander Motro Michael Fisman Enrique Z Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons Cardiovascular Diabetology |
| title | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| title_full | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| title_fullStr | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| title_full_unstemmed | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| title_short | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| title_sort | dual and pan peroxisome proliferator activated receptors ppar co agonism the bezafibrate lessons |
| url | http://www.cardiab.com/content/4/1/14 |
| work_keys_str_mv | AT tenenbaumalexander dualandpanperoxisomeproliferatoractivatedreceptorspparcoagonismthebezafibratelessons AT motromichael dualandpanperoxisomeproliferatoractivatedreceptorspparcoagonismthebezafibratelessons AT fismanenriquez dualandpanperoxisomeproliferatoractivatedreceptorspparcoagonismthebezafibratelessons |